Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Mar 20 · below the Ichimoku cloud · RSI 28 (oversold) · MACD below its signal · 3% above its 52-week low
| 9.94 | 52-week high | +147.88% |
| 5.64 | Previous month high | +40.65% |
| 4.90 | Previous month low | +22.19% |
| 4.32 | Previous week high | +7.73% |
| 4.28 | R3 (classic) | +6.82% |
| 4.18 | R2 (classic) | +4.16% |
| 4.09 | R1 (classic) | +2.08% |
| 4.07 | Previous day high | +1.50% |
| 4.01 | Price now | |
| 3.99 | Pivot | −0.58% |
| 3.90 | S1 (classic) | −2.66% |
| 3.88 | Previous day low | −3.24% |
| 3.88 | Previous week low | −3.24% |
| 3.88 | 52-week low | −3.24% |
| 3.80 | S2 (classic) | −5.32% |
| 3.71 | S3 (classic) | −7.40% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $21.1M | 0.03% | 3.44M | −8.5% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VNDA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 3, 2026 | Chrousos PhaedraDirector | Stock Award(Grant) at price 0.00 per share. | 41.6K | — |
| Jun 3, 2026 | Ward Anne SempowskiDirector | Stock Award(Grant) at price 0.00 per share. | 41.6K | — |
| Jun 3, 2026 | Mitchell Stephen RayDirector | Stock Award(Grant) at price 0.00 per share. | 41.6K | — |
| Jun 3, 2026 | Honore TageDirector | Stock Award(Grant) at price 0.00 per share. | 41.6K | — |
| Jun 3, 2026 | Duncan Charles CliffDirector | Stock Award(Grant) at price 0.00 per share. | 41.6K | — |
| Jun 3, 2026 | Mcguire Daniel PatrickGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 80K | — |
| Jun 3, 2026 | Dugan Richard WDirector | Stock Award(Grant) at price 0.00 per share. | 41.6K | — |
| May 17, 2026 | Mitchell Stephen RayDirector | Stock Gift at price 0.00 per share. | 25.8K | — |
| Apr 21, 2026 | Duncan Charles CliffDirector | Stock Award(Grant) at price 0.00 per share. | 57.1K | — |
| Mar 1, 2026 | Moran Kevin PatrickChief Financial Officer | Sale at price 8.27 per share. | 42.4K | $350.82K |
| Mar 1, 2026 | Polymeropoulos Mihael HristosChief Executive Officer | Sale at price 8.17 per share. | 156.2K | $1.28M |
| Mar 1, 2026 | Birznieks GuntherOfficer | Sale at price 8.27 per share. | 42.4K | $350.73K |
| Mar 1, 2026 | Williams Timothy IanGeneral Counsel | Sale at price 8.27 per share. | 42.4K | $350.75K |
| Mar 1, 2026 | Wijkstrom Joakim PerOfficer | Sale at price 8.27 per share. | 30.8K | $254.59K |
| Feb 22, 2026 | Honore TageDirector | Sale at price 8.03 per share. | 30K | $240.90K |
| Feb 17, 2026 | Polymeropoulos Mihael HristosChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 525K | — |
| Feb 17, 2026 | Birznieks GuntherOfficer | Stock Award(Grant) at price 0.00 per share. | 125K | — |
| Feb 17, 2026 | Williams Timothy IanGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 125K | — |
| Feb 17, 2026 | Wijkstrom Joakim PerOfficer | Stock Award(Grant) at price 0.00 per share. | 125K | — |
| Feb 17, 2026 | Moran Kevin PatrickChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 125K | — |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.5 | 18.2 | -22.4 | 2.7 | -9.2 | -5.1 | -16.7 | 5.9 | -9.1 | -18.3 | −54.5% | ||
| 2025 | -7.9 | 7.9 | -3.6 | -1.7 | -3.8 | 8.8 | -9.7 | 11.0 | 5.5 | -12.8 | 23.2 | 64.6 | +84.1% |
| 2024 | -14.7 | 24.2 | -8.1 | 15.8 | 7.4 | 10.6 | 3.4 | -9.4 | -11.3 | -0.9 | 10.8 | -7.0 | +13.5% |
| 2023 | 3.9 | -16.1 | 5.4 | -9.6 | -3.1 | 10.8 | -12.3 | -10.2 | -16.8 | 1.4 | -15.1 | 13.4 | −42.9% |
| 2022 | -3.4 | -25.1 | -0.4 | -12.3 | -0.9 | 10.9 | -1.1 | -1.9 | -6.6 | 6.0 | 4.2 | -32.3 | −52.9% |
| 2021 | 9.1 | 30.1 | -19.5 | 10.5 | 6.6 | 21.6 | -24.2 | 2.6 | 2.4 | -0.1 | -5.4 | -3.1 | +19.4% |
| 2020 | -22.3 | -13.5 | -6.1 | 11.0 | 1.9 | -2.4 | -11.9 | 2.1 | -6.1 | 10.7 | 14.2 | 7.6 | −19.9% |
| 2019 | 3.8 | -25.4 | -9.1 | -11.5 | -9.9 | -4.0 | -11.6 | 13.2 | -5.7 | 1.7 | 23.8 | -1.9 | −37.2% |
| 2018 | 4.3 | 18.9 | -10.6 | -17.2 | 26.2 | 8.2 | 9.4 | -7.3 | 18.7 | -17.3 | 32.0 | 4.4 | +71.9% |
| 2017 | -11.3 | 0.7 | -1.8 | 8.9 | -9.8 | 18.5 | -4.6 | 10.6 | 4.1 | -12.3 | -10.5 | 8.2 | −4.7% |
| 2016 | -8.4 | -8.0 | 6.5 | 6.5 | 16.9 | 7.6 | 1.9 | 34.9 | 8.2 | -10.8 | 10.8 | -3.0 | +71.3% |
| 2015 | -22.3 | -3.3 | -13.6 | -1.6 | 10.3 | 25.8 | -3.5 | -3.7 | -4.3 | -4.8 | -8.2 | -5.6 | −35.0% |
| 2014 | 6.6 | 14.4 | 7.4 | -14.3 | -26.1 | 57.2 | -9.1 | -12.0 | -19.8 | 15.7 | 8.5 | 9.9 | +15.4% |
| 2013 | 8.6 | -6.5 | 4.3 | 24.0 | 87.9 | -11.5 | 44.4 | -2.1 | -4.2 | -34.6 | 64.0 | 5.7 | +235.4% |
| 2012 | 4.0 | -6.3 | 3.2 | -7.5 | -4.1 | 3.5 | -8.4 | 8.9 | -8.2 | -15.9 | 2.7 | 6.3 | −22.3% |
| 2011 | -15.3 | -8.1 | -1.0 | 10.4 | -7.3 | -4.3 | 0.6 | -15.6 | -18.3 | 17.4 | -14.1 | -4.6 | −49.7% |
| 2010 | -11.0 | 2.6 | 12.4 | -27.2 | -13.0 | -9.6 | 9.8 | -13.2 | 6.0 | 9.4 | 10.3 | 17.4 | −15.9% |
| 2009 | 44.0 | 11.1 | 12.5 | 12.2 | 1349.5 | -19.6 | 29.1 | -10.1 | -14.8 | -12.4 | 3.5 | 6.5 | +2150.0% |
| 2008 | -37.9 | 6.8 | -15.1 | -8.8 | 32.6 | -29.7 | -69.9 | 13.1 | -16.1 | -12.8 | -20.7 | -23.1 | −92.7% |
| 2007 | 21.2 | -19.5 | 1.2 | -11.7 | -6.9 | 1.2 | -7.7 | -20.2 | -6.8 | 7.8 | -40.1 | -23.5 | −72.1% |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Buy / hold / sell counts